1. Home
  2. ENTA vs ELA Comparison

ENTA vs ELA Comparison

Compare ENTA & ELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • ELA
  • Stock Information
  • Founded
  • ENTA 1995
  • ELA 1965
  • Country
  • ENTA United States
  • ELA United States
  • Employees
  • ENTA N/A
  • ELA N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • ELA Consumer Specialties
  • Sector
  • ENTA Health Care
  • ELA Consumer Discretionary
  • Exchange
  • ENTA Nasdaq
  • ELA Nasdaq
  • Market Cap
  • ENTA 164.6M
  • ELA 146.6M
  • IPO Year
  • ENTA 2013
  • ELA N/A
  • Fundamental
  • Price
  • ENTA $8.83
  • ELA $7.18
  • Analyst Decision
  • ENTA Strong Buy
  • ELA Strong Buy
  • Analyst Count
  • ENTA 4
  • ELA 1
  • Target Price
  • ENTA $20.75
  • ELA $9.00
  • AVG Volume (30 Days)
  • ENTA 173.1K
  • ELA 37.6K
  • Earning Date
  • ENTA 08-11-2025
  • ELA 08-06-2025
  • Dividend Yield
  • ENTA N/A
  • ELA N/A
  • EPS Growth
  • ENTA N/A
  • ELA 34.09
  • EPS
  • ENTA N/A
  • ELA 0.33
  • Revenue
  • ENTA $64,806,000.00
  • ELA $198,354,109.00
  • Revenue This Year
  • ENTA N/A
  • ELA $8.82
  • Revenue Next Year
  • ENTA $4.05
  • ELA $5.45
  • P/E Ratio
  • ENTA N/A
  • ELA $22.23
  • Revenue Growth
  • ENTA N/A
  • ELA 24.35
  • 52 Week Low
  • ENTA $4.09
  • ELA $4.40
  • 52 Week High
  • ENTA $13.43
  • ELA $7.88
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 65.93
  • ELA 70.44
  • Support Level
  • ENTA $6.45
  • ELA $6.80
  • Resistance Level
  • ENTA $7.73
  • ELA $7.29
  • Average True Range (ATR)
  • ENTA 0.55
  • ELA 0.38
  • MACD
  • ENTA 0.17
  • ELA 0.10
  • Stochastic Oscillator
  • ENTA 90.15
  • ELA 84.00

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About ELA Envela Corporation

Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

Share on Social Networks: